Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245
Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.
Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.
Davis KL, Meyers J, Zhao Z, McCollam P, Murakami M. High-risk vascular disease in Japan: evidence on incidence and prevalence, patient characteristics, and treatment rates from a large Japanese claims database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 Apr; 16(3):A277.
Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2013 Feb 1;22(2):111-21.